The subject matter disclosed herein is generally directed to inhibition of XPR1 :KIDINS220-mediated phosphate export to treat cancer, in particular, ovarian and uterine cancers. The subject matter disclosed herein is also generally directed to determining cancer dependency on phosphate export by detecting the expression of SLC34A2. Compositions for inhibiting XPR1 :KIDINS220-mediated phosphate export are also described.

Anaplasma phagocytophilum surface protein AipA and/or fragments thereof which comprise an invasin domain are used in compositions suitable to elicit an immune response to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. AipA proteins and protein fragments or antibodies directed to AipA proteins and protein fragments are also used in diagnostic assays to detect exposure to and/or infection with Anaplasmatacaea. AipA and/or fragments thereof are also used for these purposes in combination with one or both of Asp14 and OmpA proteins and/or fragments thereof which comprise an invasin domain. Homologs of these proteins are also used in the compositions and assays.

Disclosed is a method for manufacturing a monoclonal antibody without using animal individuals. This method includes a step of introducing a DNA fragment comprising a gene that encodes a secretory signal, a gene that encodes a nanobody, and a gene that encodes a peptide barcode, or a vector containing the DNA fragment, into a yeast cell; and a step of collecting a polypeptide comprising the nanobody and the peptide barcode that has been expressed in the cell and secreted to the outside of the cell. According to the method, it is possible to manufacture a monoclonal nanobody more efficiently in a shorter period of time without using animal individuals.

This disclosure provides various TcBuster transposases and transposons, systems, and methods of use.

The present application provides a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.

The present invention relates to a use of a peptide containing an amino acid sequence represented by SEQ ID NO: 1 derived from the Rv2626c protein of Mycobacterium tuberculosis for treating sepsis. The peptide is excellent in inhibiting the inflammatory response induced by macrophages and is excellent in inhibiting the increase in the number of bacterial colonies, and thus can be usefully used for the treatment of sepsis.

The present invention relates to heterodimerically-tethered bispecific protein complexes (according to the general formula of A-X:Y-B) and libraries/multiplexes thereof for use in research and therapy and in particular an in vitro/ex vivo method of detecting synergistic biological function of otherwise unknown pairs of targets.

Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.

The present invention relates to a method for preparing glycine-thymosin β4 (Gly-Tβ4). The present invention has an excellent effect in that, according to the present invention, a large amount of high-purity Gly-Tβ4 can be obtained with high productivity through chromatography, enzyme treatment, and filtration of a sample containing GST fusion thymosin β4 (GST-Tβ4).

This disclosure provides various TcBuster transposases and transposons, systems, and methods of use.